Incredibly, no major CEO initially came out in direct support of Frazier, though Meg Whitman of HPE and Paul Polman of Unilever did stand by Frazier by midday. Frazier is a not only a highly admired leader, but a very effective CEO. In this era plagued by short-termism, he championed the long-term investment of 12% to 15% of revenues into R&D with great success. He has led this $40 billion firm to soaring scientific, financial, and public health triumphs. Merck has produced more new medicines than any of its peer competitors, including the newly cleared Keytruda, which helps the 160,000 people a year felled by lung cancer. Plus, Frazier has been one of the most outspoken critics of abusive drug pricing, identifying villains by name and working his trade association to help identify abuses.